The Twitter newsroom is packed with biopharma writers

After I had just finished wrapping up my daily missive from FierceBiotech yesterday, a tweet caught my eye at the corner of the screen. @adamfeuerstein from TheStreet had just picked up the first word that Dendreon's Provenge had been approved.  Inside of a few minutes, the editorial team at FierceBiotech had nailed down a news link to the report and added it to the top of our online news round-up for the day. You had it in your e-mail queue while the first reports were still spitting off...